# Trade Mark Journal No.2026/008 20 February 2026

## UK00004336207 5 February 2026 (5)

Mark 1

Mark 2

Mark 3

Mark 4

Mark 5

Renodyra

Mark 6

RENODYRA

Class 5
  Pharmaceuticals; pharmaceutical products for the treatment of disease of the genitourinary system; pharmaceutical products for the treatment of crystallopathy; pharmaceutical products for the treatment of urinary stone disease; pharmaceutical products for the treatment of kidney stone disease; pharmaceutical products for the treatment of renal calculus disease; pharmaceutical products for the treatment of renal calculus; pharmaceutical products for the treatment of kidney stones; pharmaceutical products for the treatment of recurrent renal calculus; pharmaceutical products for the treatment of recurrent kidney stones; pharmaceutical products for the treatment of hypocitraturia; pharmaceutical products for the treatment of chronic calcium oxalate stone; pharmaceutical products for the treatment of recurrent uric acid lithiasis; pharmaceutical products for the treatment of renal tubular acidosis; pharmaceutical products for the treatment of renal tubular acidosis with calcium nephrolithiasis; pharmaceutical products for the treatment of renal tubular acidosis; pharmaceutical products for the treatment of recurrent uric acid lithiasis without calcium lithiasis and cysteine lithiasis; pharmaceutical products for the treatment of recurrent uric acid lithiasis with calcium lithiasis and cysteine lithiasis.

Penlan Healthcare Limited

Representative: Swindell & Pearson Limited